Rare Diseases
🌏 NMPANMPA news and analysis for pharmaceutical BD, investment, and market access
Gain critical insights into global orphan drug development & rare disease market trends. Stay ahead in pharma R&D, investment, and regulatory strategy.
Showing 1–12 of 14 articles
Quick answer
NovaPharmaNews Rare Diseases hub for NMPA covers 14 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
PMDA Regulatory Updates: New Orphan Drug Portal and ASEAN Symposium Open
Ironwood Pharmaceuticals Survey Reveals Critical Gaps in Short Bowel Syndrome TPN Treatment at DDW 2026
Arrowhead Pharmaceuticals Receives TGA Approval for REDEMPLO (Plozasiran) in Australia for Rare Genetic Disorder
FDA Approves Travere's FILSPARI for FSGS Treatment in Adults and Children 8+
China Clinical Trial Regulations: Key Insights on NMPA Reforms 2024
Argo Biopharma Doses First Patient in Phase I Trial of siRNA Therapy BW-50218 for TTR-Related Disease
BioMarin Completes $3 Billion Acquisition of Amicus Therapeutics, Expands Rare Disease Portfolio with Galafold and Pompe Therapies
Spinogenix Launches Phase 2b/3 CLARITY Trial of SPG601 for Fragile X Syndrome Treatment
Argo Biopharma Begins Phase II Trials of BW-40202 siRNA Therapy for Rare Kidney Diseases
NMPA Accelerated Approval Pathway: Impact on China's Innovative Drug Market
PMDA SAKIGAKE Designation: Accelerating Regenerative Medicine Market Access in Japan
NMPA Priority Review Pathway: Accelerating Oncology & Rare Disease Drug Approvals
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.